Ernexa Therapeutics Inc.
No enriched coverage for $ERNA in the last 7 days.
No SEC Form 4 filings for $ERNA in the last 30 days.
CAMBRIDGE, Mass., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Ernexa Therapeutics ( NASDAQ:ERNA ) , an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will present at Cell 2025, Oxford Global's premier event, being held ...
The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1 study in platinum-resistant ovarian cancer ( PROC ) , ...
CAMBRIDGE, Mass., Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Ernexa Therapeutics ( NASDAQ: ERNA ) , developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjeev Luther, will participate in a featured panel ...
